FDA hits Hutchmed, Junshi drugs with CRLs — further clarifying its stance on China-only data

The FDA is firmly shutting the door to China-only data when it comes to approving new cancer drugs — with some exceptions.

Just over a month …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA hits Hutchmed, Jun­shi drugs with CRLs — fur­ther clar­i­fy­ing its stance on Chi­na-on­ly da­ta